Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC

Group 1 - Novartis CEO Vas Narasimhan believes the company has an agreement with the U.S. to protect it from tariffs, citing a $23 billion investment in manufacturing as a defensive measure [1] - U.S. President Donald Trump announced a plan to impose 10% tariffs on several European countries, which will increase to 25% by June 1, as part of a broader economic strategy [2] - The pharmaceutical sector in Europe is likely to be significantly affected by these tariffs, as medicines and related products represent one of the EU's largest exports to the U.S., totaling €84.4 billion ($98.1 billion) in the first three quarters of the previous year [3]